
News|Articles|November 1, 2005
Pipeline Preview
Muraglitazar (Pargluva, Bristol-Myers Squibb, Merck) for the treatment of type 2 diabetes.
Advertisement
Approvable designations
Fast-track designations
Orphan drug designations
Non-approvable designations
Newsletter
Get the latest industry news, event updates, and more from Managed healthcare Executive.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Global MS analysis links disability burden to rising economic strain
2
HS patients on biosimilar adalimumab lose response faster than those on the original drug
3
New drug class shows promise for geographic atrophy
4
CMS negotiates a 70% discount for Ozempic and Wegovy
5






















































